Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models

Diabetes

Volumn 60, Issue 3, 2011, Pages 867-875

  McGuire, Helen M ^a,b   Walters, Stacey ^a,b   Vogelzang, Alexis ^a,b   Lee, Carol M Y ^a,b   Webster, Kylie E ^a,b   Sprent, Jonathan ^a,b   Christ, Daniel ^a,b   Grey, Shane ^a,b   King, Cecile ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; FC RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 21 RECEPTOR FC RECEPTOR; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; DIABETES MELLITUS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOPATHOGENESIS; INSULITIS; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, NEUTRALIZING; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; INFLAMMATION; INTERLEUKINS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED NOD; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79952403576     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1157     Document Type: Article

References (55)

1. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-485 (Pubitemid 40563177)
2. Bach JF, Mathis D. The NOD mouse. Res Immunol 1997;148:285-286 (Pubitemid 27435910)
3. Green EA, Flavell RA. The initiation of autoimmune diabetes. Curr Opin Immunol 1999;11:663-669
4. Gazda LS, Charlton B, Lafferty KJ. Diabetes results from a late change in the autoimmune response of NOD mice. J Autoimmun 1997;10:261-270 (Pubitemid 27286533)
5. André-Schmutz I, Hindelang C, Benoist C, Mathis D. Cellular and molecular changes accompanying the progression from insulitis to diabetes. Eur J Immunol 1999;29:245-255 (Pubitemid 29043542)
6. Scharp DW, Lacy PE, Santiago JV, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990;39:515-518 (Pubitemid 20111437)
7. Stratta RJ. Review of immunosuppressive usage in pancreas transplantation. Clin Transplant 1999;13:1-12 (Pubitemid 29110382)
8. Castaño L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990;8:647-679 (Pubitemid 20135642)
9. Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol 2004;4:259-268 (Pubitemid 38478661)
10. Datta S, Sarvetnick NE. IL-21 limits peripheral lymphocyte numbers through T cell homeostatic mechanisms. PLoS ONE 2008;3:e3118
11. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci USA 2008;105:14028-14033
12. Sutherland AP, Van Belle T, Wurster AL, et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009;58:1144-1155
13. Leonard WJ, Zeng R, Spolski R. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol 2008;84:348-356
14. Kasaian MT, Whitters MJ, Carter LL, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002;16:559-569 (Pubitemid 34442580)
15. Liu S, Lizée G, Lou Y, et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol 2007;19:1213-1221 (Pubitemid 47500644)
16. Allard EL, Hardy MP, Leignadier J, et al. Overexpression of IL-21 promotes massive CD8+ memory T cell accumulation. Eur J Immunol 2007;37:3069-3077 (Pubitemid 350138977)
17. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009;324:1569-1572
18. Fröhlich A, Kisielow J, Schmitz I, et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009;324:1576-1580
19. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009;324:1572-1576
20. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-483 (Pubitemid 47123514)
21. Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007;448:484-487 (Pubitemid 47123515)
22. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008;26:57-79 (Pubitemid 351600371)
23. Meguro A, Ozaki K, Oh I, et al. IL-21 is critical for GVHD in a mouse model. Bone Marrow Transplant 2010;45:723-729
24. Bucher C, Koch L, Vogtenhuber C, et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 2009;114:5375-5384
25. Oh I, Ozaki K, Meguro A, et al. Altered effector CD4+ T cell function in IL-21R-/- CD4+ T cell-mediated graft-versus-host disease. J Immunol 2010;185:1920-1926
26. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol 1999;163:4335-4341 (Pubitemid 29474500)
27. Kurrer MO, Pakala SV, Hanson HL, Katz JD. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:213-218 (Pubitemid 27027189)
28. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998;102:516-526 (Pubitemid 28376154)
29. Corbett JA, McDaniel ML. Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J Exp Med 1995;181:559-568
30. Meredith M, Rabaglia ME, Corbett JA, Metz SA. Dual functional effects of interleukin-1beta on purine nucleotides and insulin secretion in rat islets and INS-1 cells. Diabetes 1996;45:1783-1791 (Pubitemid 26398960)
31. Zumsteg U, Frigerio S, Holländer GA. Nitric oxide production and Fas surface expression mediate two independent pathways of cytokineinduced murine beta-cell damage. Diabetes 2000;49:39-47 (Pubitemid 30022922)
32. Serreze DV, Chapman HD, Varnum DS, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med 1996;184:2049-2053
33. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002;298:1630-1634 (Pubitemid 35387203)
34. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007;178:3822-3830 (Pubitemid 46417651)
35. Young DA, Hegen M, Ma HL, et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007;56:1152-1163 (Pubitemid 46608640)
36. Faveeuw C, Gagnerault MC, Lepault F. Isolation of leukocytes infiltrating the islets of Langerhans of diabetes-prone mice for flow cytometric analysis. J Immunol Methods 1995;187:163-169
37. McGuire HM, Vogelzang A, Hill N, Flodström-Tullberg M, Sprent J, King C. Loss of parity between IL-2 and IL-21 in the NOD Idd3 locus. Proc Natl Acad Sci USA 2009;106:19438-19443
38. Walters S, Webster KE, Sutherland A, et al. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009;182:793-801
39. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-277 (Pubitemid 38496245)
40. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008;29:127-137
41. Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA. Very slow turnover of beta-cells in aged adult mice. Diabetes 2005;54:2557-2567 (Pubitemid 41233576)
42. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004;173:900-909 (Pubitemid 38924263)
43. Yamamoto H, Monden M, Kawai M, et al. The role of CD8+ and CD4+ cells in islet allograft rejection. Transplantation 1990;50:120-125 (Pubitemid 20221811)
44. Nickerson P, Steiger J, Zheng XX, et al. Manipulation of cytokine networks in transplantation: false hope or realistic opportunity for tolerance? Transplantation 1997;63:489-494
45. Ryu S, Kodama S, Ryu K, Schoenfeld DA, Faustman DL. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. J Clin Invest 2001;108:63-72 (Pubitemid 32634923)
46. Chong AS, Shen J, Tao J, et al. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 2006;311:1774-1775
47. Serreze DV, Gallichan WS, Snider DP, et al. MHC class I-mediated antigen presentation and induction of CD8+ cytotoxic T-cell responses in autoimmune diabetes-prone NOD mice. Diabetes 1996;45:902-908 (Pubitemid 26225506)
48. Kay TW, Parker JL, Stephens LA, Thomas HE, Allison J. RIP-beta 2-microglobulin transgene expression restores insulitis, but not diabetes, in beta 2-microglobulin null nonobese diabetic mice. J Immunol 1996;157:3688-3693 (Pubitemid 126449185)
49. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol 2006;177:5236-5247 (Pubitemid 44527596)
50. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005;175:2261-2269 (Pubitemid 41113833)
51. Baan CC, Balk AH, Dijke IE, et al. Interleukin-21: an interleukin-2 dependent player in rejection processes. Transplantation 2007;83:1485-1492 (Pubitemid 46934072)
52. Lee Y, Chin RK, Christiansen P, et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 2006;25:499-509 (Pubitemid 44376723)
53. Simon G, Parker M, Ramiya V, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 2008;57:405-414
54. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-127 (Pubitemid 24018655)
55. Isaacs JD. T cell immunomodulation - the Holy Grail of therapeutic tolerance. Curr Opin Pharmacol 2007;7:418-425 (Pubitemid 47296656)